Beacon Therapeutics

Beacon Therapeutics is a privately held company located in Alachua, Florida. Founded in 2023, the company employs 76 people and generates approximately $50 million in annual revenue. Beacon Therapeutics is an ophthalmic gene therapy company focused on developing treatments for a variety of retinal diseases that lead to blindness. Their current programs target X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (AMD), and cone-rod dystrophy (CRD). Their lead development candidate, AGTC-501, is a gene therapy in Phase II clinical trials for XLRP, a genetic disorder that causes progressive vision loss in males. The company's scientific foundation includes a late-stage development candidate for XLRP and two preclinical programs. Beacon Therapeutics also utilizes a target generation technology platform to identify and screen secreted proteins in the ophthalmology field. For more information, visit www.beacontx.com.